Breaking News: BriaCell Therapeutics Announces Pricing of $5.5 Million Public Offering in 2024!

PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) —

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of an underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares at a combined public offering price of $0.75 per share and associated warrant. The warrants will have an exercise price of $0.9375 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance. All of the common shares and associated warrants in the offering are being offered by the Company. Total gross proceeds from the offering, before deducting underwriters discounts and other offering expenses, are expected to be approximately $5.55 million. The offering is expected to close on December 13, 2024, subject to satisfaction of customary closing conditions. The Company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.

Now that’s some exciting news! BriaCell Therapeutics is making moves in the biotechnology world with their latest announcement. With a focus on developing cutting-edge immunotherapies to revolutionize cancer treatment, this public offering is a significant step for the company. The pricing of 7,400,000 common shares and warrants at a competitive rate of $0.75 per share shows confidence in the company’s potential.

Investors will be keeping a close eye on this offering, as the gross proceeds of $5.55 million will provide BriaCell Therapeutics with the necessary funds to further their research and development efforts. This could potentially lead to breakthroughs in cancer care and improve the lives of many patients worldwide.

With the offering set to close on December 13, 2024, stakeholders are eagerly awaiting the outcome and the impact it will have on the company’s future trajectory. BriaCell Therapeutics’ strategic approach to fundraising and innovation positions them as a key player in the biotechnology industry.

How will this affect me?

As an investor, the pricing of the public offering by BriaCell Therapeutics presents a unique opportunity to potentially invest in a company that is at the forefront of cancer treatment research. The competitive pricing of the shares and warrants, as well as the expected proceeds from the offering, could lead to future growth and returns on investment. It’s important to conduct thorough research and consider the potential risks and rewards before making any investment decisions.

How will this affect the world?

BriaCell Therapeutics’ public offering signifies a significant advancement in the field of cancer care and immunotherapy. The funds raised from the offering will enable the company to continue developing innovative treatments that could have a transformative impact on the way cancer is treated globally. As advancements are made in this area, patients around the world stand to benefit from more effective and targeted therapies, ultimately improving outcomes and quality of life.

Conclusion

In conclusion, BriaCell Therapeutics’ announcement of a $5.5 million public offering marks a pivotal moment for the company and the biotechnology industry as a whole. With a focus on revolutionizing cancer care through novel immunotherapies, this offering provides the necessary resources for BriaCell to continue their research efforts and potentially make groundbreaking discoveries. Investors, patients, and stakeholders alike are eagerly anticipating the impact of this offering and the future developments that will follow.